We are beginning to reap the benefits of the upsurge in multi-and single-site clinical trials with newer pharmacological agents that began in the mid-1990s. Although we eagerly await publications on large industry-sponsored trials currently in progress, this is a good time to take stock of the current and older literature on pharmacotherapy for PTSD. The two major developments are publica tion of guidelines on best pharmacotherapeutic prac tices in PTSD and recent approval by the Food and Drug Administration (FDA) of sertraline as a treat ment for PTSD.
Best practices. Two recent publications address the question of best practices in pharmacotherapy from somewhat different perspectives. The empirical evidence on drug efficacy is thoroughly evaluated in a chapter by Friedman et al. (in press ) that will appear in the forthcoming treatment guideline com missioned by the International Society for Trau matic Stress Studies (ISTSS). This comprehensive overview evaluates results from both randomized and open label trials and determines the level of evidence for the efficacy of each medication that has been the focus of an article in the PTSD treatment literature. A very different kind of overview is represented in a recent monograph summarizing the responses of an expert consensus panel of 57 international experts to a questionnaire on prescrib ing preferences for PTSD (Foa et al., 1999) . There are some very interesting differences between these two practice guidelines. Conclusions in the ISTSS chapter (Friedman et al., in press) are based on empirical data derived from monotherapy efficacy studies. In contrast, the panel of experts (Foa et al., 1999) offer opinions based on clinical experience on complex treatment questions about treatment strat egies for partial and non-responders to medication treatment as well as on questions about what to prescribe for patients with co-morbid psychiatric, medical, and chemical abuse/dependency disor ders.
Selective serotonin reuptake inhibitors (SSRIs) . FDA approval of sertraline as the first medication indi cated for treating PTSD patients is an important milestone in our field. The data that convinced the FDA to take this action came from two large multisite trials in which approximately 200 subjects (in each trial) were randomly assigned to either sertraline or placebo, respectively. A description of the first of these studies is currently in press (Brady et al., in press). Since results of the second trial are still being prepared for publication, I have included an ab stract of the data that were presented at a scientific meeting (Davidson, Londborg, et al., 1997 ). Both studies demonstrate what others have previously reported from single-site trials with sertraline, paroxetine, fluvoxamine, and fluoxetine: that selec tive serotonin reuptake inhibitors have a broad spec trum of action on all three (re-experiencing, avoidant/numbing, and hyperarousal) clusters of PTSD symptoms (Davidson, Malik, et al., 1997; Marmar et al., 1996; Marshall et al., 1998; Rothbaum et al., 1996) . Van der Kolk and associates (1994) , who conducted the first randomized clinical trial with the SSRI fluoxetine, also found clear evidence for the efficacy of this agent, although their results suggest a more constricted spectrum of action since it re duced numbing and hyperarousal, but not re-expe riencing or avoidant PTSD symptoms.
Randomized clinical trials (RCTs) . I have presented abstracts of all the randomized clinical trials con ducted with PTSD patients since I believe that that is the best and most valuable data in this field. Citations on SSRI trials have already been discussed. Chronologically speaking, the first trials were with older antidepressants, tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). Three studies with TCAs, all with Vietnam veteran subjects, report positive results with imipramine (Kosten et al., 1991) , mild-to-moderate effects with amitriptyline (Davidson et al., 1990) , and negative results with desipramine (Reist et al., 1989) . Two trials with the MAOI phenelzine report very posi tive results in one study (Kosten et al., 1991) and negative results in a methodologically flawed inves tigation (Shestatzky et al., 1988) . Although interest in these older agents has waned because of the more recent interest generated by SSRIs and other new agents, it is important to consider the fact that nei ther TCAs nor MAOIs have been systematically evaluated and that there may be good reasons to include them in future drug trials.
Other RCTs worth noting are a negative trial with the benzodiazepine, alprazolam (Braun et al., 1990) , a negative trial with the second messenger, inositol, which had previously shown promise in treatment of depression and panic disorder (Kaplan et al., 1996) , and a negative trial with the serotonin antago nist cyproheptadine, which had previously appeared
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PTSD RESEARCH QUARTERLY WINTER 2000 to reduce PTSD flashbacks and traumatic nightmares (Jacobs-Rebhun et al., in press). The published results from two large multi-site trials with brofaromine must be men tioned. This interesting medication combines an SSRI ac tion with reversible MAO-A inhibition. Findings with brofaromine were modestly promising in one study (Katz et al., 1994 (Katz et al., /1995 and negative in another (Baker et al., 1995) . This is only of academic interest, however, since its manufacturer has withdrawn brofaromine from the mar ket and it is not available to clinicians.
Results from open trials. The remainder of the literature consists of open trial and case reports on a number of medications that are often utilized by practitioners despite the fact that there is little published evidence to support such prescribing practices. The best study of this sort is with the adrenergic beta receptor antagonist, propranolol, which was administered to 11 sexually and physically abused children with good results. Propranolol was ad ministered according to an A-B-A design: six week baselinesix week active treatment-six week post-treatment after discontinuation of treatment (Famularo et al., 1988) . Other open trials worth noting are a successful open trial of the SSRI sertraline for patients with co-morbid PTSD and alcohol dependence (Brady et al., 1995) ; this study stands out as a model for clinical trials designed to treat PTSD and a comorbid psychiatric disorder simultaneously. Given the high prevalence of comorbid disorders in PTSD pa tients, this strategy needs to be emulated in future re search. Positive results with the reversible MAO-A inhibi tor moclobemide (Neal et al., 1997) are of great interest, since this agent is much easier to prescribe than traditional MAOIs such as phenelzine. Only one small open trial with nefazadone has been published (Hertzberg et al., 1998) , despite the fact that this antidepressant is widely pre scribed by clinicians and greatly favored by the expert consensus panel mentioned earlier (Foa et al., 1999) . Rep resentative open trials with a variety of medications are also cited for the sake of completeness, although in every case much more research is needed. These include reports concerning the anticonvulsant carbamazepine (Lipper, 1990) ; the antidepressant trazadone (Hertzberg et al., 1996) ; the adrenergic alpha-2 agonist, clonidine (Harmon & Riggs, 1996) ; and an interesting report on dramatically mixed results with the experimental narcotic antagonist, nalmafene (Glover, 1993) .
Treatment of recently traumatized individuals. As the PTSD field begins to emphasize early intervention for popula tions at risk, three studies are worth noting concerning pharmacotherapy. The most exciting of these is a success ful prospective trial of the TCA imipramine for pediatric burn patients with Acute Stress Disorder (Robert et al., 1999) . Second, a prospective trial of Israeli emergency room patients with benzodiazepines was not successful (Gelpin et al., 1996) -further evidence that there is little evidence supporting the use of this class of medications to prevent or ameliorate core PTSD symptoms. Third, a pilot study in which the hypnotic temazepam was adminis tered specifically to promote better sleep among patients with Acute Stress Disorder suggested that such an ap proach might reduce the development of PTSD after expo sure to traumatic stress (Mellman et al., 1998) . Friedman and colleagues (1993) present guidelines for pharmaco therapy for recently evacuated medical and psychiatric casualties during war.
Review articles. There are also a number of review articles that should be useful for anyone who wishes to understand this literature. Davidson et al. (1997) consider response characteristics of patient cohorts treated with antidepres sants in randomized clinical trials; important questions such as predicting responsivity, latency of detectable thera peutic effect, and other matters are thoughtfully addressed. Donnelly et al. (1999) review the disappointingly small literature on medication treatment for children and adoles cents. Friedman (in press) reviews the psychobiology of PTSD and predicts new classes of pharmacological agents that need to be developed and tested in the future.
There are also a number of older reviews that should not be forgotten because they discuss clinical trials that tend to be overlooked in more recent reviews. The most compre hensive review on TCAs is by ver Ellen and van Kammen (1990) ; on MAOIs by DeMartino et al. (1995) ; and on ethnopharmacology and the treatment of PTSD by Lin et al. (1996) . Southwick et al. (1994) Interpreting the data. There are many questions about the published data regarding gender, type of trauma, comorbidity, and chronicity. Most clinical trials with women include women exposed to sexual trauma. Most clinical trials with men involve Vietnam veterans exposed to warzone trauma. Furthermore, the male cohorts have tended to have more comorbid disorders and greater chronicity and severity of their PTSD. Therefore, it would be a serious mistake to interpret the findings of van der Kolk et al. (1994) as demonstrating greater responsivity of women than men, or greater responsivity of sexual trauma than of war-zone trauma survivors to Drug X or Drug Y. Future research must systematically evaluate the importance of gender, type of trauma, comorbidity, chronicity, and other factors as predictors of response to medication.
After a five-year hiatus, research on pharma cotherapy for PTSD began to increase in the mid-1990s. Much of this activity was spurred by the interest of phar maceutical companies in testing the efficacy of SSRIs and related agents on patients with PTSD. Such activity has not only resulted in FDA approval of sertraline and multisite trials with other agents such as nefazadone but has also stimulated the development of new classes of drugs, such as corticotropin releasing factor antagonists, substance P antagonists, and new anticonvulsants such as lamotrigine to consider that older agents such as antiadrenergic agents, and gabapentin (see Friedman, in press) that may eventuMAOIs, anticonvulsants, and possibly TCAs may yet find ally prove efficacious in PTSD. As we are swept along by their niche in PTSD pharmacotherapy after they have been this exciting momentum, however, we should not neglect evaluated systematically.
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BAKER, D.G., DIAMOND, B.I., GILLETTE, G.M., HAMNER, M.B., KATZELNICK, D., KELLER, T.W., MELLMAN, T.A., PONTIUS, E.B., ROSENTHAL, M., TUCKER, P., VAN DER KOLK, B.A., & KATZ, R.J. (1995) . A double-blind, randomized, pla cebo-controlled, multi-center study of brofaromine in the treat ment of post-traumatic stress disorder. Psychopharmacology, 122, [386] [387] [388] [389] . A large multi-center, double-blind, parallel trial to assess the efficacy of brofaromine in the treatment of PTSD failed to show a significant difference between the brofaromine and pla cebo treatment groups. The placebo response rate in this study was higher than that in previously published double-blind, pla cebo-controlled studies of PTSD. A total of 187 outpatients with a DSM-III-R diagnosis of PTSD and a Clinician Administered PTSD Scale part 2 (CAPS-2) minimal total score > 50 at baseline (73% were female, mean age 40 years, mean duration of illness 12 years, 61% were the victims of physical or sexual assault). MAIN OUTCOME MEASURES: Baseline-to-endpoint change in CAPS-2 total severity score, the Impact of Event Scale total score (IES), and Clinical Global Im pression Severity (CGI-S), and CGI-Improvement (CGI-I) ratings at endpoint. RESULTS: Sertraline treatment yielded significantly (p < 0.02) greater improvement on 3 out of the 4 primary outcome measures, with the fourth measure, the IES, showing a trend toward significance (p = 0.071). Using a conservative LOCF analysis, treatment with sertraline resulted in a responder rate of 53% at study endpoint compared to 32% for placebo (p = 0.008; with responder defined as > 30% reduction from baseline in CAPS-2 total severity score and a CGI score of 1 (very much improved), or 2 (much improved). Significant (p < 0.05) efficacy was evident for sertraline from week 2 on the CAPS-2 total severity score. Sertraline had significant efficacy vs. placebo on the PTSD symptom clusters of avoidance/numbing (p = 0.015) and increased arousal (p = 0.027) but not on the reexperiencing/ intrusion (p = 0.143). The beneficial effect of sertraline was con firmed by a highly significant improvement both on the patientrated Davidson Trauma Scale (DTS; p = 0.003), as well as on functional and quality of life measures. Sertraline was welltolerated, with insomnia being the only side effect significantly different from placebo (16% vs. 4%). CONCLUSIONS: The re sults of this study suggest that sertraline is a safe, well-tolerated, and effective treatment for PTSD. BRADY, K.T., SONNE, S.C., & ROBERTS, J.M. (1995) . Sertraline treatment of comorbid posttraumatic stress disorder and alco hol dependence. Journal of Clinical Psychiatry, 56, 502-505. BACK GROUND: PTSD often co-occurs with alcohol dependence, yet little is known about treatment of this comorbidity. The serotonin selective reuptake inhibitors have been shown preliminarily to be effective in decreasing symptoms of PTSD but have not been studied in individuals with comorbid alcohol dependence. This is of particular interest as the SSRIs also have a modest effect in decreasing alcohol consumption. METHOD: In this preliminary trial, 9 subjects with comorbid PTSD and alcohol dependence were treated in an open-label trial with sertraline for a 12-week period. Symptoms of PTSD and depression were monitored monthly with the Impact of Event Scale and the Hamilton Rating Scale for Depression (HAM-D). Alcohol consumption was moni tored by a self-report instrument (Time-Line Follow-Back). RE SULTS: There were significant decreases in all 3 symptom clus ters of PTSD measured by overall PTSD symptom scores (p < .001) and in HAM-D scores (p < .001) during the follow-up period. Days of abstinence increased and average number of drinks decreased during the follow-up period. 4 subjects claimed total abstinence during the follow-up period. CONCLUSION: While limited by small sample size and the open-label, nonblinded study design, this study suggests that sertraline may be useful in the treatment of PTSD complicated by alcoholism. The medica tion was well tolerated and subjects showed improvement in PTSD symptoms as well as decreased alcohol consumption. A controlled trial of sertraline in this population would be of interest. Psychiatry, 47, [259] [260] [261] [262] [263] [264] [265] [266] . Amitriptyline hydrochloride was compared with placebo in 46 veterans with chronic PTSD. Treat ment continued up to 8 weeks, and efficacy was measured by five observer and two self-rated scales. Percent recovery rates were higher for amitriptyline than placebo on two measures. In pa tients who completed 4 weeks (n = 40), better outcome with amitriptyline was noted on the Hamilton depression scale only. In the group completing 8 weeks of treatment (n = 33), the drug was superior to placebo on Hamilton depression, Hamilton anxi ety, Clinical Global Impression severity, and Impact of Event scales. There was no evidence for drug effects on the structured interview for PTSD. Drug-placebo differences were greater in the presence of comorbidity in general, although recovery rates were uniformly low in the presence of major depression, panic disor der, and alcoholism. At the end of treatment, 64% of the amitrip tyline and 72% of the placebo samples still met diagnostic criteria for PTSD. th Annual Meeting, 147. The lifetime prevalence of PTSD has been reported to be 7.8% in the general population and twice as common in females as in males. Symp toms can persist for years after the traumatic event. A multi center, 12-week, double-blind, flexible dose study of adult outpa tients (n = 208) with a DSM-III-R diagnosis of PTSD was con ducted at 12 U.S. centers to evaluate the safety and efficacy of sertraline (50-200 mg/day) compared to placebo in the treatment of PTSD. The primary efficacy ratings were the Impact of Event Scale (IES), the Clinician Administered PTSD Scale (CAPS) and the Clinician Global Impression ratings of severity and improve ment. At endpoint, sertraline patients exhibited significantly (p < .05) greater improvement than placebo patients on all primary efficacy measures. Sertraline-treated patients experienced mean decreases of approximately 49% and 44% in IES and CAPS scores respectively, compared to approximately 35% mean reductions on both the IES and CAPS scores in placebo-treated patients. The Davidson Self-Rating Trauma scale (DTS) was administered as a secondary efficacy measure, and at endpoint sertraline-treated patients exhibited a mean decrease of approximately 43% com pared to 27% in the placebo group (p < .01). Sertraline was generally well tolerated. The most frequently reported adverse events (>10%) that occurred significantly more in sertraline treated patients than placebo-treated patients were insomnia, diarrhea, nausea, fatigue, and anorexia. Treatment discontinuations due to adverse events occurred in approxi mately 10% of the sertraline-treated patients compared to 5% of the placebo-treated patients, and this difference was not statisti cally significant. There were no clinically meaningful changes in laboratory values nor any significant changes in vital signs or ECGs between treatment groups. In this study, sertraline in doses of 50-200 mg/day was shown to be a safe and effective treatment for patients with PTSD. International Clinical Psychopharmacology, 12, [291] [292] [293] [294] [295] [296] . Characteristic response patterns are described for 2 antidepressant drugs and placebo in PTSD. Early onset and steady improvement occurred on a global rating scale for both drugs and placebo in those who ultimately met re sponder criteria at the end of treatment. In certain cases, the magnitude of global response was greater for drug than for placebo. At weeks 2 or 4, the Clinical Global Impressions score for fluoxetine, but not for amitriptyline, served as a good predictor of eventual response. In a review of numerous completed placebocontrolled trials, antidepressants were superior to placebo in 7 out of 8 comparisons using the Clinical Global Impressions, although specific effects on PTSD scales were more variable. Drug response rates are similar for combat and civilian trauma samples, but placebo response rates may be higher in the latter. Effect sizes suggested a moderate-to-good effect for drug therapy.
FAMULARO, R., KINSCHERFF, R., & FENTON, T. (1988) . Propranolol treatment for childhood posttraumatic stress dis order, acute type. American Journal of Diseases of Children, 142, 1244-1247. We report 11 cases of PTSD. Each child had been physically abused or sexually abused or both and presented in an agitated, hyperaroused state. Using a B-A-B (off-on-off) medica tion design in a clinical setting, the children were treated with the beta-adrenergic antagonist propranolol. Scores on an inventory of symptoms of PTSD indicated that patients exhibited signifi cantly fewer symptoms while receiving medication than either before or after they received medication. Guilford. PTSD appears to be a very complex disorder that is associated with stable and profound alternatives in many psychobiological systems that have evolved for coping, adaptation, and survival of the human species. The most substantial available evidence supports the use of the broad category of antidepressant medications, especially SSRIs, which appear to promote global improvement in most, but not all, randomized clinical trials. Antiadrenergic agents such as clonidine, guanfacine, and propanolol may prove to ameliorate arousal and reexperiencing symptoms by reducing the excessive adrenergic activity associated with PTSD. Unfortunately there is very little clinical data to substantiate this speculation at this time. There is a great deal of evidence suggesting that pharmaco therapy will successfully reduce most disorders comorbid with PTSD. There is good reason to anticipate exciting breakthroughs in the foreseeable future that should equip clinicians with a greater variety of effective drugs that will benefit patients with PTSD. (pp. 465-481) . Philadelphia: LippincottRaven. We review the current literature on the clinical psychopharmacology of PTSD. With our growing appreciation of the complexity of PTSD, we are beginning to understand why we may have failed to discover a single drug that will significantly reduce PTSD symptoms. There have been too few published randomized clinical trials. Even among these few published RCT's, there are enough questions about methodology, instru mentation, and sample selection to suggest the need for expan sion and extension of RCT programs to include testing and retesting of more drugs. Despite these concerns, it does appear that certain drugs may be helpful in alleviating specific PTSD symptom clusters. A rational approach to pharmacotherapy for PTSD may require a multisystem approach in which multiple drugs, each one with a unique and distinct action, are adminis tered simultaneously. Theory and retrospective research pre dict that early treatment may be more efficacious. Specifically, high-potency benzodiazepines have been recommended for the treatment of acute responses to trauma and for prevention of PTSD. This study prospectively evaluates the effect of early administration of benzodiazepines on the course of PTSD and PTSD symptoms. METHOD: 13 trauma survivors (the benzodi azepine group) were treated within 6.7 + 5.8 days after the trauma (range, 2-18) with either clonazepam (n= 10, 2.7 + 0.8 mg/day) or alprazolam (n = 3, 2.5 mg/day). 13 other trauma survivors, pairmatched with subjects in the active treatment group for gender and symptom severity in the first week after the trauma, consti tute the control group. Both groups were reevaluated 1 and 6 months after the trauma for PTSD symptoms (Horowitz Impact of Event Scale; Mississippi Rating Scale for Combat-Related PTSD civilian trauma version), PTSD status (Clinician Adminis tered PTSD Scale), state anxiety, depression, and resting heart rate. RESULTS: Subjects in the benzodiazepine group did not differ from controls in 1-month and 6-month PTSD and anxiety scores. Repeated measures ANOVA showed no group or groupby-time effect on psychometric measures. A trend toward groupby-time interaction in resting heart rate was noted (progressive decrease in the benzodiazepine group). 9 benzodiazepine sub jects and 3 controls met PTSD diagnostic criteria 6 months after the trauma. CONCLUSION: Contrary to expectations, the early administration of benzodiazepines to trauma survivors with high levels of initial distress did not have a salient beneficial effect on the course of their illness, while reducing physiologic expres sion of arousal. KATZ, R.J., LOTT, M.H., ARBUS, P., CROCQ, L., HERLOBSEN, P., LINGJAERDE, O., LOPEZ, G., LOUGHREY, G.C., MACFARLANE, D.J., MCIVOR, R., MEHLUM, L., NUGENT, D., TURNER, S.W., WEISAETH, L., & YULE, W. (1994 /1995 . Phar macotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety, 1, 169-174. This was a multicenter, ran domized, double-blind, parallel trial conducted in outpatients in three countries. Following screening and placebo washout, pa tients received brofaromine (a combined MAO-A inhibitor/5 HT transport inhibitor) or placebo in a flexible dosing design.
Based upon the CAPS, a standardized PTSD interview, findings from a cohort involving both subchronic and chronic traumatic stress marginally favored brofaromine over placebo; however, not to a statistically significant degree. With a more conservation [sic] definition of the syndrome, employing a primary cohort of patients with PTSD of one year or greater duration, brofaromine significantly reduced PTSD symptoms in comparison with pla cebo. In all analyses a substantial proportion of patients in both drug and placebo groups remained symptomatic throughout. Findings were supported by an analysis of secondary measures. Brofaromine may be of benefit in the therapy of PTSD. KOSTEN, T.R., FRANK, J.B., DAN, E., MCDOUGLE, C.J., & GILLER, E.L. (1991) . Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease, 179, [366] [367] [368] [369] [370] . 60 male veterans with PTSD partici pated in an 8-week, randomized trial comparing phenelzine (n = 19), imipramine (n = 23), and placebo (n = 18). Mean treatment retention was better on phenelzine (7.4 weeks) than on imi pramine (5.6 weeks) or placebo (5.5 weeks). By week 5, both medications significantly reduced PTSD symptoms, as assessed by the Impact of Event Scale (IES), but the 44% improvement on phenelzine was greater than the 25% improvement on imipramine. The intrusion, but not the avoidance, subscale of the IES showed significant improvement, and the initial mild to moderate de pressive symptoms did not significantly improve. Issues, research, . Washington: Ameri can Psychological Association. In this chapter, we first review the principles of how ethnicity may interact with drug metabolism and drug action. Next, the role that ethnicity plays in relation to the specific classes of medications that are commonly used to treat PTSD -antidepressants, neuroleptics, benzodiazepines, and lithium -is covered. Finally, we briefly discuss future research directions and the applicability of this research to clinical prac tice.
REIST, C., KAUFFMANN, C.D., HAIER, R.J., SANGDAHL, C., DEMET, E.M., CHICZ-DEMET, A., & NELSON, J.N. (1989) . A controlled trial of desipramine in 18 men with posttraumatic stress disorder. American Journal of Psychiatry, 146, [513] [514] [515] [516] male U.S. veterans meeting DSM-III criteria for PTSD completed a 4-week double-blind, crossover study comparing administra tion of 200 mg/day of desipramine with placebo. Response was measured by using the Beck Depression Inventory, the Hamilton Rating Scale for Depression, the Hamilton Rating Scale for Anxi ety, and the Impact of Event Scale. Overall, the only apparent response to desipramine was in some symptoms of depression; there were no changes in anxiety and other PTSD symptoms.
ROBERT, R., BLAKENEY, P.E., VILLARREAL, C., ROSENBERG, L., & MEYER, W.J. (1999) . Imipramine treatment in pediatric burn patients with symptoms of acute stress disor der: A pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 38, [873] [874] [875] [876] [877] [878] . OBJECTIVE: Pediatric burn patients often exhibit acute stress disorder (ASD) symptoms. Information on psychopharmacological treatment of ASD symp toms in children is scarce. This pilot study used a prospective, randomized, double-blind design to test whether thermally in jured children suffering ASD symptoms benefit from imipramine. METHOD: 25 children, aged 2 to 19 years, received either imi pramine or chloral hydrate for 7 days. A structured interview (clinically useful, but validity and reliability not yet established) was used to assess the presence and frequency of ASD symptoms both before treatment and 3 times during the treatment period. RESULTS: 11 females and 14 males participated, with a mean total burn surface of 45% (SD = 23%) and mean age of 8 years (SD = 6). Imipramine was more effective than choral hydrate in treating ASD symptoms (χ2 [1, n = 25] = 5.24, p < .02). Five of 13 were positive responders to chloral hydrate (38%). Ten of 12 were positive responders to low-dose imipramine (83%). CONCLU SIONS: This pilot study suggests a place for cautious initial use of imipramine to reduce ASD symptoms in burned children. Care must be taken to minimize cardiovascular risks in an off-label application of imipramine in children, especially those receiving additional medications. SHESTATZKY, M., GREENBERG, D., & LERER, B. (1988) . A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatry Research, 24, [149] [150] [151] [152] [153] [154] [155] . 13 patients meeting DSM-III criteria for PTSD participated in a random-assignment, doubleblind crossover trial comparing phenelzine (45-75 mg/day) and placebo. 10 patients completed at least 4 weeks of each treatment phase. Clinical response to phenelzine did not differ from pla cebo, and overall improvement by the end of the study could not be attributed to the active drug. The findings are discussed in the light of preliminary reports suggesting that phenelzine may be an effective treatment for PTSD. VAN DER KOLK, B.A., DREYFUSS, D., MICHAELS, M.J., SHERA, D., BERKOWITZ, R., FISLER, R.E., & SAXE, G.N. (1994) . Fluoxetine in posttraumatic stress disorder. Journal of Clinical Psychiatry, 55, [517] [518] [519] [520] [521] [522] . Background: This study was designed to establish the efficacy of the serotonin reuptake blocker fluoxetine in the treatment of PTSD. Method: 64 subjects (22 women and 42 men; 31 veterans and 33 nonveterans) with PTSD entered a 5 week randomized double-blind trial comparing fluoxetine (n = 33) and placebo (n = 31). Results: By Week 5 fluoxetine, but not placebo, significantly reduced overall PTSD symptomatology, as assessed by the Clinician-Administered PTSD Scale (CAPS) score. Changes were most marked in the arousal and numbing symp tom subcategories. Non-VA patients responded much better than VA patients. Fluoxetine was an effective antidepressant independent of its effects on PTSD. Conclusion: Fluoxetine is an effective pharmacotherapeutic agent for treating PTSD and its associated features, particularly in patients without chronic treat ment histories. (1996) . Inositol treatment of post-traumatic stress disorder. Anxiety, 2, 51-52. Administered inositol, a second messenger system precursor, to 13 patients with PTSD due to either combat or civilian trauma, drawn from two clinics. Using a double-blind placebo-controlled cross-over design, the authors found no effects of treatment on PTSD symptoms. Patients at one site showed some improve ments in depression. 
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